American journal of translational research最新文献

{"title":"Effects of regional citrate anticoagulation on clinical outcome and complications in continuous renal replacement therapy for acute kidney injury.","authors":"Li Zhang, Run Liu","doi":"10.62347/MVGE5925","DOIUrl":"https://doi.org/10.62347/MVGE5925","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the effect of regional citrate anticoagulation (RCA) on clinical outcome, renal function, and bleeding complications in patients with acute kidney injury (AKI) undergoing continuous renal replacement therapy (CRRT).</p><p><strong>Methods: </strong>This retrospective study reviewed medical records of 180 patients treated at the Second Affiliated Hospital of Hainan Medical University from January 2020 to January 2023. Patients were divided into two groups based on anticoagulation strategy: 85 patients who received systemic heparin anticoagulation (control group, CG) and 95 patients who received RCA (research group, RG). The clinical efficacy, adverse reactions, and incidence of bleeding complications were compared between the groups. Changes in renal function [blood urea nitrogen (BUN) and serum creatinine (Scr)] and coagulation values [prothrombin time (PT), activated partial thromboplastin time (APTT), and platelet count (PLT)] before and after treatment were also analyzed.</p><p><strong>Results: </strong>The total effective rate was significantly higher in the RG compared to the CG (P<0.05). The incidence of adverse reactions was 12.94% in the CG and 8.42% in the RG, with no statistically significant difference (P>0.05). However, the incidence of bleeding complications was significantly lower in the RG (P<0.05). After treatment, both groups showed significant reductions in BUN and Scr, with the RG exhibiting lower levels than the CG (both P<0.05). In both groups, PT and APTT increased while PLT decreased, but these values were more favorable in the RG (all P<0.05). Logistic regression analysis identified age, AKI stage, and treatment method as independent risk factors influencing treatment efficacy (all P<0.05). Additionally, post-treatment levels of hypersensitive C-reactive protein (hs-CRP) and interleukin-4 (IL-4) decreased in both groups, with the RG showing significantly lower levels than the CG (all P<0.05).</p><p><strong>Conclusion: </strong>RCA is effective for AKI patients undergoing CRRT, improving renal and coagulation function, reducing the risk of adverse reactions and bleeding, and demonstrating a favorable safety profile.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"17 2","pages":"1302-1310"},"PeriodicalIF":1.7,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909514/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the bioactive properties and mechanism of <i>Aegle marmelos</i> in the treatment of inflammatory bowel disease through network pharmacology and a molecular docking approach.","authors":"Bhagyabhumi Shah, Nilay Solanki","doi":"10.62347/GCCV5213","DOIUrl":"https://doi.org/10.62347/GCCV5213","url":null,"abstract":"<p><strong>Background: </strong>Inflammatory bowel diseases (IBD) are recurrent inflammatory conditions that occur in the gastrointestinal tract, for which current treatment does not have satisfactory results, thus we require new therapies to combat the complex pathogenesis of IBD. Herbal medicines have been used for years to cure IBD. One of the plants from Ayurveda, <i>Aegle marmelos</i> (AM), commonly known as Bael, which belongs to the family Rutaceae, has ethnomedicinal properties in treating IBD due to its various phytochemicals. However, the mechanisms underlying the effect of AM remain to be elucidated.</p><p><strong>Methods: </strong>In this study, an <i>in silico</i> approach, molecular docking, and enrichment analysis were implemented to uncover the potential multicomponent synergistic effect and its molecular mechanism in treating IBD. Putative targets of IBD were obtained through OMIM, GeneCards, and DisGeNET databases. Compounds of AM were screened for their targets using a Swiss target prediction database and Super-PRED database. The common targets amongst AM and IBD were analyzed and the network was constructed using Cytoscape (3.10.0). Protein-protein interactions of target genes of the compounds was carried out through a STRING database. Then, the INPUT database was used to analyze the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway. Molecular docking of top 6 compounds with hub targets was carried out using Autodock vina.</p><p><strong>Results: </strong>In the study, 46 effective compounds and 358 targets of AM were identified and further analyzed, 80 hub targets depending on the degree were considered effective against IBD. Through CytoHubba we identified AKT1, SRC, MAPK3, MAPK1, EGFR, IL6, TNF, HSP90AA1 and CASP3 as the top 10 hub targets that may contribute to the mechanistic role of AM in treating IBD. Aegeline, auraptene, bergapten, imperatorin, marmesin, and nodakenin were the most potent compounds of AM and those that possess a higher binding affinity to PI3K, AKT, and EGFR. PI3-AKT signaling pathway, EGFR tyrosine kinase inhibitor, and MAP Kinase signaling pathway are the major pathways having a correlation with AM.</p><p><strong>Conclusion: </strong>The study unveils the mechanism of AM in alleviating IBD through the EGFR-mediated PI3K/AKT pathway, stating its multi-component, multi-targeted therapeutic efficacy through multiple pathways.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"17 2","pages":"748-769"},"PeriodicalIF":1.7,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909509/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of traditional Chinese medicine combined with Chinese massage therapy for enhancing cervical function in cervical spondylosis: a meta-analysis.","authors":"Fanghan Cui","doi":"10.62347/LLLF4360","DOIUrl":"https://doi.org/10.62347/LLLF4360","url":null,"abstract":"<p><strong>Objective: </strong>To determine the relative effectiveness of Traditional Chinese medicine (TCM) formula combined with Chinese massage therapy (Tui Na) for cervical spondylosis (CS).</p><p><strong>Methods: </strong>A comprehensive search was conducted across multiple databases, including Wanfang, CNKI, Chinese Biomedical Literature, VIP, Embase, PubMed, Cochrane Library, and Web of Science. Studies were screened to include randomized controlled trials (RCTs) that examined the efficacy of TCM combined with Tui Na for CS. The clinical curative effect was evaluated by analyzed the effective rate, pain level (Visual Analogue Scale, VAS), and Neck Disability Index (NDI) score. Pooled and sensitivity analyses were performed, and risk of bias was evaluated.</p><p><strong>Results: </strong>A total of 11 studies met the inclusion criteria. Compared to Chinese Message therapy alone, TCM combined with Tui Na exhibited a more pronounced reduction in VAS score (SMD: -1.72; 95% CI = [-2.57, -0.86]; I² = 94.5%, P < 0.001) and also a significant improvement in NDI score (SMD = -0.61; 95% CI = [-1.78, 0.56]; P < 0.0001). The combined treatment resulted in a higher clinical efficacy compared to Tui Na alone (SMD: 0.87; 95% CI = [0.80-0.95]; I² = 0%, P = 0.978), although the difference was not statistically significant. Quality of life were significantly improved in CS patients treated with combined therapy (SMD = 1.06, 95% CI = [0.03-2.09], P = 0.001).</p><p><strong>Conclusion: </strong>Traditional Chinese medicine encapsulation combined with Chinese massage therapy is effective in treating cervical spondylosis, significantly reducing the pain levels and improving cervical vertebral function.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"17 2","pages":"1321-1334"},"PeriodicalIF":1.7,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909565/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 worsens quality of life in elderly heart failure patients: a clinical study.","authors":"Zhangxing Luo, Yun Jiao, Binwu Ma","doi":"10.62347/ATQD2701","DOIUrl":"https://doi.org/10.62347/ATQD2701","url":null,"abstract":"<p><strong>Background: </strong>The coronavirus disease 2019 (COVID-19) pandemic has significantly worsened the health and quality of life of vulnerable populations, particularly elderly patients with heart failure. This study aimed to assess the effect of COVID-19 infection on the quality of life in elderly patients with heart failure during the pandemic.</p><p><strong>Methods: </strong>This retrospective case-control study included elderly heart failure patients admitted to the Second People's Hospital of Lanzhou between December 2022 and December 2023, all of whom were diagnosed during the ongoing COVID-19 pandemic. All patients underwent COVID-19 nucleic acid testing upon admission. Among the 96 heart failure patients who tested positive for COVID-19 and the 68 who tested negative, multiple validated instruments were used to assess both physical and mental health quality of life. These instruments included the Minnesota Living with Heart Failure Questionnaire (MLHFQ), 36-Item Short Form Health Survey physical component summary score (SF-36 PCS), 6-Minute Walking Test (6MWT), Geriatric Depression Scale-15 (GDS-15), Self-Rating Anxiety Scale (SAS) Total, Pittsburgh Sleep Quality Index (PSQI), Mini Nutritional Assessment-Short Form (MNA-SF), and the Fatigue, Resistance, Ambulation, Illness, and Loss of weight (FRAIL) Scale.</p><p><strong>Results: </strong>Heart failure patients who tested positive for COVID-19 exhibited significantly lower blood pressure, SF-36 scores, and 6MWT distances compared to those who tested negative (P<0.05). Additionally, the COVID-19-positive group had higher MLHFQ scores, older average age, a greater proportion of patients in NYHA class III-IV, more frequent electrolyte imbalances, elevated D-dimer, C-reactive protein (CRP), and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, and longer hospital stays (P<0.05). These patients also exhibited higher levels of anxiety (SAS total), poorer sleep quality (PSQI), and greater frailty (FRAIL Scale) compared to their COVID-19-negative counterparts (P<0.05). In addition, heart failure patients with COVID-19 infection reported more severe symptoms of dyspnea and fatigue (P<0.05). Both age and COVID-19 infection were identified as significant factors negatively affecting the quality of life in this patient population.</p><p><strong>Conclusion: </strong>COVID-19 infection significantly exacerbates the decline in quality of life in elderly patients with heart failure. This highlights the urgent need for strengthened, comprehensive treatment and targeted mental health support for this vulnerable group.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"17 2","pages":"1416-1427"},"PeriodicalIF":1.7,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909553/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy, safety, and effect on platelet activation of the timing of administration of tirofiban in patients with acute ischemic stroke.","authors":"Mingjia Wang, Fan Zhang, Qian Guo, Wan Wang, Kejun Wu, Hua Chen","doi":"10.62347/JUCB8921","DOIUrl":"https://doi.org/10.62347/JUCB8921","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the efficacy, safety, and effects on platelet activation of tirofiban administered at different times in patients with acute ischemic stroke, with the goal of providing precise guidance for clinical treatment timing.</p><p><strong>Methods: </strong>A total of 262 patients with acute ischemic stroke admitted to No. 215 Hospital of Shaanxi Nuclear Industry between January 2021 and June 2023 were retrospectively analyzed. Patients were divided into an early treatment group (ETG, n = 124) and a late treatment group (LTG, n = 138) based on the timing of tirofiban administration. The ETG received tirofiban within 6 hours after thrombolysis, while the LTG received it 6 to 24 hours after thrombolysis. Clinical efficacy was evaluated post-treatment, and adverse reactions during treatment were recorded. Comparisons were made for pre- and post-treatment National Institutes of Health Stroke Scale (NIHSS) scores, Modified Rankin Scale (mRS) scores, neurological function markers, coagulation factors, inflammatory markers, and homocysteine (Hcy) levels. Correlations between efficacy and post-treatment indicators were analyzed, and logistic regression identified factors influencing outcome.</p><p><strong>Results: </strong>The ETG demonstrated significantly better overall efficacy than the LTG (P = 0.004). Post-treatment NIHSS and mRS scores, neuron-specific enolase (NSE), platelet-activating factor (PAF), high-sensitivity C-reactive protein (hs-CRP), Hcy, and interleukin-1β (IL-1β) levels were significantly lower in the ETG, while brain-derived neurotrophic factor (BDNF) levels were higher (all P < 0.001). Clinical efficacy correlated significantly with post-treatment mRS scores, PAF levels, and Hcy levels (all P < 0.001). The ETG also had significantly lower rates of re-occlusion (P = 0.001), cardiopulmonary complications (P = 0.004), and symptomatic cerebral hemorrhage (P = 0.035). Logistic regression showed that the LTG was associated with reduced efficacy (β = -4.469, P = 0.019), while higher post-treatment PAF (β = 2.437, P < 0.001) and Hcy levels (β = 1.782, P = 0.013) were linked to poorer outcome.</p><p><strong>Conclusion: </strong>Early administration of tirofiban in acute ischemic stroke offers significant clinical benefits, including improved neurological function and enhanced daily living abilities, with reduced inflammatory response and complications.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"17 2","pages":"791-805"},"PeriodicalIF":1.7,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909562/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Magnesium cantharidate inhibits hepatocellular cancer by targeting RACK1.","authors":"Da Sun, Xiaofei Li, Meichen Liu, Zhenfu Chen, Lingjun Wang, Rong Yan","doi":"10.62347/PGAK3727","DOIUrl":"https://doi.org/10.62347/PGAK3727","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study was to investigate whether magnesium cantharidate (MC) exerts anti-hepatocellular carcinoma (anti-HCC) effects by targeting receptor for activated C kinase 1 (RACK1).</p><p><strong>Methods: </strong>The Cancer Genome Atlas (TCGA) database was used to analyze the expression of RACK1 in liver tissues. Molecular docking was used to examine the binding interactions between MC and RACK1. Huh-7 and SK-Hep-1 liver cancer cells' viability, proliferation, and apoptosis were assessed by using the Cell Counting Kit-8 (CCK-8) assay, 5-ethynyl-2'-deoxyuridine (EdU), and flow cytometry, respectively. RNA sequencing was used to explore the underlying mechanisms. Quantitative real-time PCR, immunohistochemistry, and western blotting were performed to explore the expression of key genes and proteins.</p><p><strong>Results: </strong>TCGA analysis revealed significant upregulation of RACK1 in liver cancer tissues that was correlated with tissue type, grade, TP53 mutation, and overall survival. Molecular docking results revealed that the minimum binding energy between MC and RACK1 was -5.8 kcal/mol. Moreover, RACK1 overexpression significantly promoted cell viability and proliferation, and inhibited apoptosis in liver cancer cells. However, MC significantly reversed the viability, proliferation, and apoptosis effects induced by RACK1 overexpression in liver cancer cells. MC significantly inhibited the growth of subcutaneously transplanted tumors <i>in vivo</i>. RNA sequencing revealed that MC inhibited proliferation and apoptosis by targeting RACK1 to regulate calcium ion transport, ion channels, and cell adhesion in liver cancer cells.</p><p><strong>Conclusion: </strong>MC exerts anti-HCC effects by targeting RACK1.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"17 2","pages":"1178-1199"},"PeriodicalIF":1.7,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909533/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel approaches to improve systemic bioavailability of curcumin using probiotics for rotenone-induced Parkinson's disease in rodents.","authors":"Arun Soni, Adarsh Patel, Sanjeev Acharya, Alkesh Patel, Umang Shah, Swayamprakash Patel, Nilay Solanki, Mehul Patel","doi":"10.62347/TKQK8110","DOIUrl":"https://doi.org/10.62347/TKQK8110","url":null,"abstract":"<p><strong>Background and aim: </strong>The prevalence of Parkinson's Disease (PD) is high, and treatment is not optimal to date. Curcumin possesses neuroprotective effects. Nevertheless, oral use is incommodious due to its poor bioavailability. Numerous attempts have been made to increase its systemic bioavailability. Among these, an effective way to increase the bioavailability of curcumin is by combining it with probiotics to target the glucuronidation reaction. The present study focuses on the bio-enhancement of curcumin using probiotics in animal models of PD by alleviating oxidative stress and ameliorating dopamine levels.</p><p><strong>Materials and methods: </strong>Forty-two male rats were used for the study. Twelve animals were used for a bio-availability study in which curcumin was administered orally alone and concomitantly with a probiotic (<i>Lactobacillus Rhamnus</i>, 10⁹ <i>cfu</i>, PO) to prove probiotics' ability to enhance curcumin's serum level by inhibition of β-glucuronidase activity. Serum curcumin level was estimated using the LC-MS/MS technique on 21 days of dosing. The remaining animals were used in an experimental study. PD was induced through 2.5 mg/kg rotenone (ROT). Subsequently, the animals were allocated to five groups and treated commensurately along with ROT. Three treatment groups were administered curcumin (alone, with 10⁸ <i>cfu</i>, with 10⁹ <i>cfu</i>). The standard control and disease control groups were supplied with sunflower oil. Effect on behavioral patterns, neurotransmitter and enzyme levels, and oxidative stress parameters were measured. Moreover, the brain was isolated for histopathology.</p><p><strong>Results and conclusions: </strong>The bioavailability study revealed a significant (<i>P</i>-value <0.001) increase in the serum level of curcumin in concomitantly administered probiotics with curcumin-treated animals compared to curcumin-only treated animals. An experimental study showed improved behavioral parameters, brain dopamine level, acetylcholinesterase (AchE), and oxidative stress combined in the curcumin and <i>L. Rhamnosus</i> treated groups. A notable improvement in the histology of the brain was observed. These findings strongly indicate that combining <i>L. Rhamnosus</i> with curcumin may be an effective therapeutic solution.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"17 2","pages":"868-877"},"PeriodicalIF":1.7,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909508/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanism of PPARα agonist in alopecia areata.","authors":"Xiaomei Xuan, Guoqiang Zhang, Jinfang Zhang, Qing Zhu, Yuli Zhang, Lijuan Liu, Dandan Peng, Dongxue Wang, Yaling Liu","doi":"10.62347/JDYZ3863","DOIUrl":"https://doi.org/10.62347/JDYZ3863","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the involvement and mechanisms of PPARα agonists in alopecia areata (AA).</p><p><strong>Methods: </strong>AA models were established using skin grafting, adoptive T-cell transfer, and TCR retrograde T-cell transfer methods. Relative PPARα expression levels in C3H/HeJ AA mice and AA patients were evaluated using qPCR and immunohistochemistry (IHC). Hair changes in mice following treatment were documented photographically, while immunofluorescence staining was employed to assess inflammatory factor dynamics in the skin. Additionally, ELISA and flow cytometry were used to analyze AA-related immune factors and cell populations in treated mice.</p><p><strong>Results: </strong>PPARα agonists demonstrated protective effects in C3H/HeJ skin graft AA models and TCR transgenic AA mice, promoting early reversal of AA. They effectively inhibited T effector cell function and exerted immunomodulatory effects.</p><p><strong>Conclusion: </strong>The PPARα signaling pathway plays a key role in AA pathogenesis. PPARα agonists show therapeutic potential for AA as an inflammatory condition.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"17 2","pages":"844-855"},"PeriodicalIF":1.7,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909512/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of SOX18 in nasopharyngeal carcinoma: implications for prognosis and therapy.","authors":"Guoqian Ni, Wenbin Wang, Yuan Dang, Cui Cheng, Qiaowen Wang","doi":"10.62347/YTRV6870","DOIUrl":"https://doi.org/10.62347/YTRV6870","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the cellular function of SOX18 in nasopharyngeal carcinoma (NPC) by analyzing its effects on tumor cell proliferation, apoptosis, migration and invasion, and to verify its expression and prognostic significance by clinical samples, thereby providing a basis for precise diagnosis and treatment.</p><p><strong>Methods: </strong>SOX18 expression was analyzed in NPC cell lines and clinical samples. Gene silencing techniques were utilized to reduce SOX18 expression in NPC cells, followed by assays to evaluate cell proliferation, apoptosis, migration, and invasion. Additionally, changes in the Wnt/β-catenin signaling pathway were examined.</p><p><strong>Results: </strong>High SOX18 expression was correlated with poor survival in NPC patients. Silencing SOX18 significantly inhibited cell proliferation, increased apoptosis, and suppressed migration and invasion capabilities. Furthermore, SOX18 silencing downregulated key genes and proteins associated with the Wnt/β-catenin signaling pathway.</p><p><strong>Conclusion: </strong>SOX18 plays a critical role in NPC progression by affecting key cellular behaviors. Targeting SOX18 may offer new therapeutic strategies and improve prognostic assessments for NPC patients, highlighting its potential as a valuable molecular marker for cancer treatment.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"17 2","pages":"913-926"},"PeriodicalIF":1.7,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909540/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143647010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Esculin alleviates palmitic acid-induced intestinal barrier damage via Nrf2/HO-1 signaling.","authors":"Qinglan Song, Yongbo Wang, Yexin Tang, Lei Zhu, Deyun Lan","doi":"10.62347/NSCJ5164","DOIUrl":"https://doi.org/10.62347/NSCJ5164","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the effects and mechanisms of esculin in protecting against palmitic acid-induced intestinal barrier disruption in mice.</p><p><strong>Methods: </strong>Thirty-two male BALB/c mice were randomly assigned to four groups: control, model, esculin, and esculin+ML385 groups. A model of intestinal barrier injury was induced by daily gavage of 10 mg/kg palmitic acid for 3 days in all groups except for the control group. The esculin group received 100 mg/kg esculin orally for the same duration, while the esculin+ML385 group was additionally treated with 30 mg/kg ML385 intraperitoneally before each gavage. Disease severity was assessed using the disease activity index (DAI). TNF-α, IL-1β, IL-6, MDA, and T-AOC levels were measured using biochemical assays. mRNA expression of inflammatory and protective markers was determined using qPCR, and the protein levels of occludin, ZO-1, Nrf2, and HO-1 were detected using Western blot.</p><p><strong>Results: </strong>The DAI was significantly lower in the esculin group compared to the model group (<i>P</i> < 0.001). Serum TNF-α, IL-6, and IL-1β levels were significantly reduced in the esculin group (<i>P</i> < 0.001), while T-AOC increased and MDA decreased (<i>P</i> < 0.001). Intestinal mucosa showed elevated levels of TNF-α, IL-1β, ZO-1, Nrf2, HO-1, and occludin in the esculin group (<i>P</i> < 0.05), while ML385 reversed these protective effects.</p><p><strong>Conclusion: </strong>Esculin alleviates palmitic acid-induced intestinal barrier damage by activating the Nrf2/HO-1 signaling pathway and inhibiting inflammation, indicating its potential therapeutic role in managing intestinal barrier dysfunction.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"17 2","pages":"878-887"},"PeriodicalIF":1.7,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909530/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}